Navigation Links
New Article Sets Out 10 Vital Calls to Action Needed to Address Shortcomings and Inconsistencies in Multiple Sclerosis Management and New Treatment Development Across Europe
Date:6/9/2016

LONDON, June 9, 2016 /PRNewswire/ --

Patrick Vermersch, Ralf Gold, Chris Holloway, Àlex Rovira , Gavin Giovannoni, Mondher Toumi. European Neurological Review, 2016;11(1):41-7. http://doi.org/10.17925/ENR.2016.11.01.41

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

The opportunities and challenges of managing multiple sclerosis in countries across identified in an article published recently in European Neurological Review the peer-reviewed journal from touchNEUROLOGY. In this review, Patrick Vermersch et al, assert that despite recent therapeutic advances, there are many deficiencies in the management of multiple sclerosis (MS). Diagnostic and monitoring measures, guidelines, development of new treatments and best practice care are often suboptimal. These shortcomings were discussed at two MS multi-stakeholder colloquia that were convened in Brussels, Belgium in May 2014 and May 2015, and gathered experts from a range of different specialities to identify the key issues and propose means of tackling them. After considering all the testimony and discussion, the organising committee drew up a list of 10 calls to action, which included: increase awareness and understanding in the EU about the burden of MS; obtain better insights into the direct and indirect cost burden of MS; (re)define treatment goals and clinical study endpoints; develop new tools to better capture the total clinical burden of MS; develop a protocol to standardise magnetic resonance imaging (MRI); develop biomarkers of treatment response prediction and disability progression; integrate drug licensing and cost-effectiveness decision-making processes; develop separate European Medicines Agency guidelines for evaluating follow-on products of non-biological complex drugs and biologicals; implement a set of evidence-based standards of care and incentives to support people with MS to remain physically and mentally active. Addressing these ambitious calls to action requires cooperation from various health bodies and governments and some will require additional funding, but they are achievable and worthwhile. They would help minimise disease impact and would reduce disease progression and the consequent burden on people with MS, their caregivers, and on health budgets. These calls to action set out a strategy for future MS management and Vermersch et al believe they should be acted upon with urgency.

The full peer-reviewed, open-access article is available here:

data-omniture="http://www.touchophthalmology.com/articles/low-energy-stereotactic-radiotherapy-treatment-exudative-age-related-macular-degeneration" rel="nofollow">http://doi.org/10.17925/ENR.2016.11.01.41

Disclosure: Patrick Vermersch has received consulting fees and honoraria from Bayer Schering, Biogen Idec, Merck-Serono, Novartis, Teva, Genzyme-Sanofi, Almirall and Roche. He has also received research support from Bayer Schering, Biogen Idec, Merck-Serono, and Teva. Ralf Gold has received research support and speaker's honoraria from Bayer Schering, Biogen, Chugai, ELAN, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva and consulting honoraria from ZLB Behring, Baxter and Talecris. Chris Holloway has received honoraria or consultation fees from Teva. Alex Rovira serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, and OLEA Medical, and on the editorial board of the American Journal of Neuroradiology and Neuroradiology. He has received speaker honoraria from Bayer, Genzyme, Sanofi-Aventis, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, OLEA Medical, Stendhal, Novartis and Biogen Idec, and has research agreements with Siemens AG. Gavin Giovannoni has received personal compensation for participating on advisory boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Bayer Schering Healthcare, Biogen Idec, Canbex, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, GW Pharma, Ironwood, Merck Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals. Mondher Toumi has provided consul ting through Aix Marseille University and through Creativ- Ceutical to most companies engaged in commercialising MS products: scientific board contribution, presentation in scientific meeting, strategic consulting.

About touchNEUROLOGY 

touchNEUROLOGY (a division of Touch Medical Media) publishesEuropean Neurological Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:
Carla Denaro - Managing Editor
managingeditor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals.


'/>"/>
SOURCE touchNEUROLOGY.com
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Magnetic Insight to Collaborate with Stanford School of Medicine on Magnetic Particle Imaging to Advance Cancer Research and Neurovascular Imaging
2. Varian Medical Systems Announces Particle Therapy Scientific Advisory Board
3. Spheryxs Journal of Pharmaceutical Sciences Paper Selected to be Feature Article
4. Patent Granted for Additional Polymer Technology Originated at Particle Sciences
5. Nanoparticle Analysis Market Worth USD 91.1 Million by 2020
6. X-Ray Films, Chemicals and Processors Market 2015-2020 - Global Strategic Business Report: Rise in Use of Gold Nanoparticles in X-Ray Imaging Applications
7. Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer
8. InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy
9. IBA and Toshiba Sign Strategic Partnership in Particle Therapy
10. Immune Pharmaceuticals to Develop Novel Topical Nanoparticle Formulation of AmiKet
11. Particle Sciences Manufactures Clinical Supplies for Kinexs Glioblastoma Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
(Date:9/12/2017)...  Consumer reviews on the independent review site Consumer Affairs ... company for hearing aids, ranking it higher than Miracle Ear ... ... For Hearing Aids ... online store that provides high performance, state-of-the-art, German-engineered hearing aids directly ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: a moving compilation of ... value to God. “Letters From Home” is the creation of published author, John Allred, ... Cabinet of Jerry Savelle Ministries International, who has traveled and ministered on four continents. ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from Pixel Film Studios creating ... can select from up to two layers of subject matter along with fully customizable ... within Final Cut Pro X. , With ProSlideshow Portrait each user are ...
(Date:9/21/2017)... ... 21, 2017 , ... The American Addiction Treatment Association (AATA) ... in the addiction treatment industry entitled: Special Investigations Unit (SIU) – What ... state and federal governments are increasingly scrutinizing the addiction treatment industry for fraudulent ...
(Date:9/21/2017)... Ca (PRWEB) , ... September 21, 2017 , ... Bill ... services to its customers, and give back to the community. For over 37 years, ... the most successful companies serving plumbing in San Diego. They were chosen ...
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. ... screening tests, has received two prestigious recognitions that acknowledge the promise of its ... Preora has been named a Top 100 Finalist for the 16th annual ...
Breaking Medicine News(10 mins):